Muse bio is enabling a new era of genome engineering that will transform our understanding of biology. Muse bio delivers power to researchers and production scientists in the field of genome engineering and synthetic biology through the combination of a powerful computer aided forward design software package, a proprietary benchtop biofoundry, and custom reagents. Its next-generation, CRISPR-based ForgeCraft technology dramatically accelerates genome engineering.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/01/17 | $23,000,000 | Series B |
Foresite Capital NanoDimension Paladin Capital Group Spruce-MLS Venrock  | undisclosed |
